Updated:
Third Culture Capital
Third Culture Capital invests at the confluence of healthcare, technology, and access. The firm backs early-stage, healthcare-native startups and...
Third Culture Capital
Third Culture Capital invests at the confluence of healthcare, technology, and access. The firm backs early-stage, healthcare-native startups and unconventional founders with a Third Culture mindset. It evaluates investments against the Quintuple Aim and focuses on improving how care is delivered, accessed, and experienced across real-world systems.
General information
Firm type
Private Equity
Year founded
2020
Location
Region
North America
Country
United States
City
Boston
Corporate office
Boston, MA, United States
Principals
Julien L. Pham
Founder & Managing Partner
Sector focus
Frequently asked questions
Who makes investment decisions at Third Culture Capital?
Investment decisions are led by Julien Pham, the firm's Founder and Managing Partner. Pham is a practicing nephrologist at Brigham and Women's Hospital in Boston, which gives him direct clinical-operational context when evaluating health-tech startups. The firm has not publicly disclosed additional investment committee members or junior partners.
How does Third Culture Capital source its deal flow?
The firm's deal flow is rooted in Pham's dual identity as a clinician and investor. Sourcing channels include academic medical center networks, clinical professional societies, health-tech founder communities, and referrals from other physician-investors. This model gives early access to clinician-founders who are solving workflow problems that are invisible to non-clinical investors.
Does Third Culture Capital invest outside the United States?
The firm's primary focus is US innovation hubs — Boston, San Francisco, and New York — where the density of academic medical centers and health-tech founders is highest. Pham has evaluated deals in Toronto and London, but no cross-border portfolio companies have been confirmed as core positions.
How is Third Culture Capital's investment approach different from a typical health-tech venture fund?
The structural differentiator is Pham's ongoing clinical practice. Because he still treats patients at a major teaching hospital, the firm identifies investment opportunities through firsthand experience with clinical workflow failures, reimbursement friction, and regulatory gaps that generalist VCs only hear about secondhand. This physician-operator model is rare among institutional venture firms.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Source record modified: . Public records carry source-specific dates where available. No population-wide measured refresh cadence or universal verification deadline is established here. Page modified, source captured, fact observed, entity verified and aggregate measured describe different events. Check the date attached to the relevant claim; a missing verification date means unknown. Stored source history does not establish a customer-facing historical-analysis interface. To correct this record or make a privacy request, send the page URL and your evidence to privacy@altss.com; corrections are free.
Need institutional-grade insight on private equity firms?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: